Beta-Caryophyllene / HO-1 Cancer Research Results

β-Caryophyllene is a dietary sesquiterpene and CB2 agonist with preclinical anticancer evidence, including apoptosis induction, reduced proliferation, anti-angiogenesis, reduced invasion/migration, and chemo/radio-sensitization. Evidence is promising but remains mainly in-vitro and animal-based; clinical cancer validation is lacking.
-naturally occurring sesquiterpene found in many plant essential oils: black pepper, clove oil ...
-binds selectively to the CB2 receptors(modulates up) and not the CB1 receptor, which makes it non-psychoactive and therapeutically appealing.

Beta-Caryophyllene — β-Caryophyllene is a plant-derived bicyclic sesquiterpene hydrocarbon and dietary cannabinoid with selective functional agonism at cannabinoid receptor type 2. It is formally classified as a natural sesquiterpene terpene, food flavoring compound, and investigational phytochemical adjunct rather than an approved anticancer drug. Standard abbreviations include BCP, β-CP, and sometimes trans-caryophyllene. It occurs in multiple essential oils, especially black pepper, clove, copaiba, oregano, hops, rosemary, and Cannabis sativa chemotypes, but its database identity should be the purified compound rather than a whole-oil product.

Primary mechanisms (ranked):

1. CB2-centered anti-inflammatory and immunomodulatory signaling, with low CB1 activity and therefore no intrinsic THC-like psychoactive classification.
2. Suppression of pro-survival oncogenic signaling, especially PI3K/Akt/mTOR, STAT3, NF-κB, and related proliferation or survival pathways in cancer models.
3. Induction of mitochondrial apoptosis through Bax/Bcl-2 shift, caspase activation, mitochondrial stress, and cell-cycle arrest in several cancer cell lines.
4. Anti-angiogenic and anti-migratory activity, including inhibition of endothelial migration, tube formation, VEGF-linked responses, EMT, invasion, and metastasis-associated phenotypes.
5. Chemosensitization, mainly preclinical, reported with cisplatin and other cytotoxic or targeted agents; mechanism appears context-dependent and partly linked to apoptosis and resistance-pathway modulation.
6. Radiosensitization, currently preliminary and model-dependent, with recent colorectal cancer cell evidence involving PPARγ-mediated apoptosis.
7. ROS/NRF2 modulation is secondary and context-dependent: BCP can promote oxidative stress in cancer-cell apoptosis models, while in normal injury models it more often shows cytoprotective antioxidant and NRF2-linked effects.

Bioavailability / PK relevance: BCP is highly lipophilic and formulation-sensitive; oral exposure is limited and variable with conventional dosing, while self-emulsifying lipid formulations can substantially improve human systemic exposure. PK relevance is high because many in-vitro anticancer concentrations are unlikely to be reproduced by normal dietary intake.

Delivery constraints: The key delivery constraints are volatility, hydrophobicity, oxidation/stability, low aqueous solubility, food-matrix dependence, and the likely need for lipid, nanoemulsion, SEDDS, or other formulation strategies if systemic pharmacology is the goal.

In-vitro vs systemic exposure relevance: Most anticancer assays use micromolar-to-high-micromolar or µg/mL concentrations; these should be interpreted cautiously because common in-vitro levels likely exceed exposures achievable from culinary intake. Formulated oral BCP may improve exposure, but clinical anticancer target engagement has not been established.

Clinical evidence status: Preclinical oncology evidence is moderate and spans cell, endothelial, and animal models; human evidence is small and mostly non-oncology or PK-focused. No validated clinical cancer efficacy evidence was found. Best database status is preclinical / investigational adjunct, with possible chemosensitizer and anti-angiogenic tags marked as preclinical.

Beta-Caryophyllene Mechanistic Profile

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr